Thalia Therapeutics (LSE:THAT) EBITDA Margin %: -18,900.00% (As of Dec. 2025)


What is Thalia Therapeutics EBITDA Margin %?

Thalia Therapeutics LSE:THAT -3.70% EBITDA Margin % is -18,900.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Thalia Therapeutics ranks worse than 94.71% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Thalia Therapeutics's EBITDA for the six months ended in Dec. 2025 was £-0.76 Mil. Thalia Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Thalia Therapeutics's EBITDA margin for the quarter that ended in Dec. 2025 was -18,900.00%.

Thalia Therapeutics  (LSE:THAT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Thalia Therapeutics EBITDA Margin % Related Terms

Thalia Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Thalia Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thalia Therapeutics EBITDA Margin % Chart

Thalia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -66,750.00 -16,571.43 -17,514.29

Thalia Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34,550.00 -12,250.00 -22,333.33 -11,750.00 -18,900.00

LSE:THAT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Thalia Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thalia Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thalia Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Thalia Therapeutics's EBITDA Margin % falls into.


Thalia Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Thalia Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.226/0.007
=-17,514.29 %

Thalia Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.756/0.004
=-18,900.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -18,900.00% mean?
Thalia Therapeutics (LSE:THAT) has a EBITDA Margin % of -18,900.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Thalia Therapeutics and its competitors. According to the industry distribution chart, Thalia Therapeutics ranks #895 out of 945 companies in the Biotechnology industry, placing it in the top 94.7%.
Is Thalia Therapeutics' EBITDA Margin % too high?
Thalia Therapeutics' current EBITDA Margin % is -18,900.00%. Based on the distribution chart, Thalia Therapeutics ranks #895 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Thalia Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thalia Therapeutics ranks #895 out of 945 companies for EBITDA Margin %. This places Thalia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Thalia Therapeutics and its competitors. Thalia Therapeutics's current EBITDA Margin % is -18,900.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thalia Therapeutics stock overvalued right now?
Thalia Therapeutics (LSE:THAT) has a current EBITDA Margin % of -18,900.00%. The current EBITDA Margin % is -18,900.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Thalia Therapeutics (LSE:THAT), the current EBITDA Margin % is -18,900.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thalia Therapeutics Business Description

Other Exchanges 0GO:Germany
Address 2 Portman Street, London, GBR, W1H 6DU
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.